[Efficacy of Recombinant Activated Factor VII for Intractable Bleeding after Cardiovascular Surgery].
Recombinant activated factor VII (rFVIIa) has been used for the treatment of hemophilia, factor VII deficiency, and Glanzmann's thrombasthenia. We retrospectively reviewed the effectiveness of rFVIIa for the treatment of uncontrollable bleeding after cardiovascular surgery. Eight patients received rFVIIa for the treatment of uncontrollable bleeding after admission to the intensive care unit following cardiovascular surgery between April 2009 and July 2014. Blood loss was significantly decreased in 7 of the 8 cases after the administration of rFVIIa (p<0.05). No adverse thromboembolic events were encountered. The quantity of blood loss and prothrombin time-international normalized ratio(PT-INR), activated partial thromboplastin time(APTT), fibrin degradation products(FDP) and D-dimer levels decreased significantly after the administration of rFVIIa (p<0.05). The blood coagulation test values were almost within the normal range at 24 hours after administration. In appropriately selected patients, rFVIIa is an effective agent for the treatment of excessive bleeding after cardiovascular surgery.